Studying Heart Muscle Diseases to Find Markers of Progression
Studies patients with heart muscle disease to find markers predicting worsening heart failure.
Key facts
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Where
- Bologna, Florence, and Roma, ItalySee the 3 sites
- Trial code
- Registry title
- Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation
- Status
- Recruiting
- People taking part
- 700 people, planned
- Started
- 13 Feb 2023
- Expected to end
- 14 Dec 2027
- Type of study
- Observational
- Record updated
- 7 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 or older who have been diagnosed with cardiomyopathy (a heart muscle disease).
- Age
- 12 years or older at the time of diagnosis.
- Sex
- All sexes can join.
- Disease stage
- Cardiomyopathy diagnosed according to current international guidelines.
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients diagnosed with CMP according to current international guidelines
- Age ≥ 12 years at the time of diagnosis
- Obtaining informed consent from the patient and the parent or legal guardian (in the case of patients aged < 18 years)
Who cannot take part
- none
Where in Italy
- IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyContact: Elena Biagini, MD, PhDTaking people
- Azienda Ospedaliero-Universitaria Careggi di FirenzeFlorence, ItalyContact: Iacopo Olivotto, MDNot yet recruiting
- Dipartimento di Scienze Toraciche Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCSS di RomaRoma, ItalyContact: Francesca Graziani, MDNot yet recruiting
About the trial
What the trial wants to find out
The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus on microRNAs (miRNAs) and spatial transcriptomics, which are emerging techniques that may provide insights into the underlying disease mechanisms. By understanding these markers, the investigators hope to improve the way the investigators diagnose and manage CMP, particularly in terms of predicting progression to heart failure or heart transplantation.
Read full original descriptionShow less
The study will evaluate patients with hypertrophic cardiomyopathy (e.g., sarcomeric forms, Anderson-Fabry disease, AL, and TTR cardiac amyloidosis), dilated cardiomyopathy and arrhythmogenic cardiomyopathy. These patients will undergo clinical evaluations, including ECG, echocardiograms, CMR, biopsy analysis, and genetic testing, as well as molecular studies such as transcriptomics and miRNA analysis. This comprehensive approach aims to identify potential new biomarkers for diagnosing and predicting the disease course.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical, Instrumental, and Molecular (Circulating and Tissue microRNAs) Characterization of Patients With Cardiomyopathy to Identify Critical Patients With Severe Organ Failure to be Candidates for Cardiac Transplantation
- Plain-language title
- Studying Heart Muscle Diseases to Find Markers of ProgressionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 7 February 2025